Home › Trials › NCT06779058
Clinical trial Recruiting at 1 site Observational Ages 18 to 80

Using MR elastography to assess liver fibrosis in chronic hepatitis B patients

Official title: Retrospective and Prospective Multi-center Clinical Study of Magnetic Resonance Elastography in Evaluating Hepatic Fibrosis in Chronic Viral Hepatitis B

Run by Shengjing Hospital · NCT06779058 · Data updated 2026-11-12

This study is testing if a new imaging technique called MR elastography can help doctors better understand liver damage in adults with chronic hepatitis B without needing a liver biopsy.

Quick facts

Study typeObservational
Ages18 Years to 80 Years
SexAll
Enrollment600 (estimated)
SponsorShengjing Hospital
Academic / other
Locations1 site (Shenyang, Liaoning)
StatusRecruiting
StartedJanuary 1, 2025
Main results expectedDecember 1, 2026
Study endsDecember 1, 2026
Registry record updatedFebruary 27, 2026
Trial IDNCT06779058 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates for this study are adults aged 18 and older with confirmed chronic hepatitis B who have not yet received antiviral treatment.

Probably not a fit

Patients with liver malignancies or chronic hepatitis due to other causes, as well as those with contraindications for MRE, may not benefit from this study.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to evaluate the effectiveness of magnetic resonance elastography (MRE) as a non-invasive method for grading liver fibrosis in patients with chronic hepatitis B (CHB). The study will involve patients aged 18 and older who have confirmed CHB and will compare MRE results with liver biopsy findings. By providing a more accurate and timely assessment of liver fibrosis, the study seeks to improve clinical management and treatment decisions for CHB patients. The research will also monitor disease progression over time to enhance patient outcomes.

Why it matters

Potential benefit: If successful, this study could lead to improved non-invasive methods for assessing liver fibrosis, allowing for better management of chronic hepatitis B.

How similar studies have gone: Other studies have shown promising results using similar non-invasive imaging techniques for liver fibrosis assessment, indicating potential success for this approach.

Who can join: the full rules

Show full inclusion / exclusion criteria 
Inclusion Criteria:

* Age ≥ 18 years old
* Confirmed CHB (laboratory, imaging and clinical tests)
* MRE within 6 months before and after liver biopsy
* Treatment-naïve
* Child-Pugh Grade A (\<7 points)
* Written informed consent in prospective follow-up cohort

Exclusion Criteria:

* Patients with liver malignant tumor
* Chronic hepatitis due to other causes (such as alcoholic hepatitis)
* CHB combined with hepatitis C, hepatitis D, or HIV
* Patients with biliary tract diseases
* Contraindications of MRE examination, MRE failure
* Poor pathological effect

Where it's running

  • Shengjing Hospital
    Shenyang, Liaoning, China     Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
View on ClinicalTrials.gov ↗ Find more trials like this →
Browse more
Chronic Hepatitis B 56Liver Fibrosis 63Shengjing Hospital 40
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.